Study of Oro-cecal Transit Time in Healthy Subjects Using Scintigraphy and Lactulose Hydrogen Breath Test.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05004207 |
Recruitment Status :
Recruiting
First Posted : August 13, 2021
Last Update Posted : August 13, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Small Bowel Disease Motility Disorder Irritable Bowel Syndrome | Diagnostic Test: 99mTc Scintigraphy |

Study Type : | Observational |
Estimated Enrollment : | 50 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Oro-cecal Transit Time in Healthy Indian Subjects Using Scintigraphy and Its Correlation With Lactulose Hydrogen Breath Test- A Pilot Study |
Actual Study Start Date : | July 1, 2021 |
Estimated Primary Completion Date : | January 31, 2022 |
Estimated Study Completion Date : | January 31, 2022 |

- Diagnostic Test: 99mTc Scintigraphy
After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.
Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device.
Other Name: Lactulose Hydrogen Breath test
- Oro-caecal transit time (OCTT) using lactulose hydrogen breath test (LHBT) and scintigraphy study. [ Time Frame: six months ]LHBT is the commonly used test for OCTT, but it has fallacies, since it itself increase intestinal motility, so this study aims to validate LHBT with scintigraphy which is the gold standard test.
- Normative data for OCTT using nuclear scintigraphy in healthy indian population. [ Time Frame: six months ]There is no reference values for nuclear scintigraphy in healthy indian patients. The study will help generate data to give reference values for OCTT using scintigraphy.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
• Healthy individual > 18 years of age with no comorbidities
Exclusion Criteria:
- Thoracic or digestive foregut surgery,
- Alcohol consumption >40 g/day,
- Use of medications that alter intragastric acidity or oesophageal motility
- History of diabetes mellitus, thyroid disorder
- Neurological disorders
- Chronic gastrointestinal disease
- Any subject with upper GI symptoms like pain, burning, belching, bloating, dysphagia & aerophagia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05004207
Contact: Neeraj Singla, MBBS, MD, DM | 7888619216 ext 91 | dr.neerajsingla@gmail.com | |
Contact: Aniruddha P Singh, MBBS, MD, DM | 9004093248 ext 91 | draniruddhapratapsingh@gmail.com |
India | |
AIG Hospitals | Recruiting |
Hyderabad, Telangana, India, 500032 | |
Contact: Aniruddha P Singh, MBBS,MD,DM 09004093248 draniruddhapratapsingh@gmail.com | |
Contact: Neeraj Singla, MBBS,MD,DM 07888619216 dr.neerajsingla@gmail.com |
Study Director: | Rakesh kalapala, MBBS, MD, DM | Senior Consultant | |
Principal Investigator: | Pratik Chhabra, MBBS, MD | Fellow | |
Principal Investigator: | Suneetha B, MBBS, MD, DM | Consultant |
Responsible Party: | Rakesh Kalapala, Senior Consultant, Asian Institute of Gastroenterology, India |
ClinicalTrials.gov Identifier: | NCT05004207 |
Other Study ID Numbers: |
AIG/IEC-BH&R 15/06.2021-02 |
First Posted: | August 13, 2021 Key Record Dates |
Last Update Posted: | August 13, 2021 |
Last Verified: | August 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There is no plan to share individual participant data. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Small bowel disease Orocaecal transit time nuclear scintigraphy lactulose hydrogen breath test |
Intestinal Diseases Irritable Bowel Syndrome Gastrointestinal Diseases Digestive System Diseases |
Colonic Diseases, Functional Colonic Diseases Lactulose Gastrointestinal Agents |